Lupus & antiphospholipid syndrome
N-terminal pro-brain natriuretic peptide is a biomarker for cardiovascular damage in systemic lupus erythematous: a cross-sectional study
Authors' conclusion
NT-proBNP is a biomarker for CV damage in SLE.
Study context
- Population
- Unselected systemic lupus erythematosus (SLE) patients enrolled in the MUHC Lupus Clinic registry; serum collected March 2022–April 2023 at annual research visitsfemale 91%
- Participants
- 270 patients
- Exposure
- NT-proBNP and cardiovascular damage in SLE
- Outcome
- CVD identified on the SLICC Damage Index
Methodological detailsregistry-based, multivariable logistic regression
- Registry-based
- Multivariable logistic regression
Main finding
As reported in the abstract
Association of NT-proBNP with CVD
- Patients with cardiovascular damage (CVD)
- 33 (12%)
- AUC of NT-proBNP for CVD
- 0.78 (95% CI 0.69-0.87)
- Best-discrimination threshold of NT-proBNP
- 133 pg/ml
- NT-proBNP >133 pg/ml associated with CVD, multivariable OR
- 7.0 (95% CI 2.6-19.1)
- Hypertension associated with CVD, multivariable OR
- 3.3 (95% CI 1.2-9.0)
- Dyslipidaemia associated with CVD, multivariable OR
- 3.6 (95% CI 1.3-9.6)
Observational data: associations, not effects.
Further findings
Factors associated with increased NT-proBNP levels
- Age, OR
- 4.2 (95% CI 2.2-8.3)
- Ever smoking, OR
- 1.9 (95% CI 1.0-3.5)
- Reduced eGFR
- 4.1 (95% CI 1.3-13.1)
- Prior pericarditis/pleuritis, OR
- 2.5 (95% CI 1.4-4.5)
- aPL antibodies, OR
- 2.6 (95% CI 1.4-4.9)
Original publication
N-terminal pro-brain natriuretic peptide is a biomarker for cardiovascular damage in systemic lupus erythematous: a cross-sectional study. Rheumatology (Oxford). Published 6 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →